Society of Hematologic Oncology

Watch our interview with Dr. Andrew Kuykendall on the RALLY-MF trial from

Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial https://youtu.be/hJ9ApvP62ac?is=N_xmsYKDd8NWZM7v Andrew Kuykendall, MD, an associate member from Moffitt Cancer Center, discusses updated data from the phase 2 RALLY-MF trial. The trial evaluated DISC-0974 in patients with myelofibrosis and anemia. DISC-0974 is a first-in-class monoclonal antibody d...

FDA grants fast track designation to STX-0712 in relapsed or refractory CMML

FDA grants fast track designation to STX-0712 in relapsed or refractory CMML The US Food and Drug Administration has granted fast track designation to the investigation therapy STX-0712 for the treatment of patients with relapsed or refractory chronic myelomonocytic leukemia. STX-0712 is a CyTAC™ (cytotoxicity targeting chimera) targeting the the CCR2 receptor, highly expr...

Which AML patients get lasting benefit from olutasidenib?

Which AML patients get lasting benefit from olutasidenib? Participants with relapsed rather than refractory AML, as well as females, were more likely to get a durable response from the oral IDH1 inhibitor olutasidenib (Rezlidhia), according to a new analysis of pivotal trial data. The drug was evaluated in a phase II registrational study in IDH1-mutated re...

Join our regional partners in Kuwait for the LLS & SOHO Joint Meeting 2026: Controversies in Hematological Malignancies.

Register here: quotehubkw.com/chm26/

Anito-cel manufacturing builds on CAR T-cell learnings in multiple myeloma trials

Anito-cel manufacturing builds on CAR T-cell learnings in multiple myeloma trials Anitocabtagene autoleucel (anito-cel), an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, was successfully manufactured for the majority of participants with relapsed or refractory or newly diagnosed multiple myeloma in the iMMagine-3 and GEM-AnitoFIRST trials, according to a poster presen...

SOHO will be at ! Visit us at our booth to learn about our great programs and how you can be involved in the society. Learn more at sohoonline.org.

Anthony Goldstone built a transplant program. It started in a broom cupboard.

Anthony Goldstone built a transplant program. It started in a broom cupboard. Not many haematologists can say their clinical journey began in a broom cupboard. Anthony Goldstone can. “Starting with a single patient in a broom cupboard—almost literally—we built a world-ranked programme that has treated thousands from across the UK and around the world,” he said. Prof. ...

Frontline tafasitamab, lenalidomide plus R-CHOP improves outcomes in B-cell lymphomas

Frontline tafasitamab, lenalidomide plus R-CHOP improves outcomes in B-cell lymphomas Tafasitamab plus lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) improved progression-free survival (PFS) compared with R-CHOP alone and had manageable safety for patients with aggressive B-cell lymphomas in the phase 3 frontMIND study, according to a presentation at the 2026 ASCO Annual Meeting. The fro...

Addition of ibrutinib to R-da-EPOCH in HIV-related DLBCL may improve survival outcomes

Addition of ibrutinib to R-da-EPOCH in HIV-related DLBCL may improve survival outcomes A study presented by Ida Wong-Sefidan, MD, of the University of California, San Diego, and colleagues at the 2026 ASCO Annual Meeting found that adding ibrutinib to R-da-EPOCH (dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) for patients with HIV-related d...